MGA 012

Drug Profile

MGA 012

Alternative Names: MGA012

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 26 Jan 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03406949)
  • 05 Dec 2017 MacroGenics closes the global collaboration and license agreement with Incyte Corporation for MGA012
  • 25 Oct 2017 MacroGenics enters into an agreement to license MGA 012 to Incyte for worldwide development and commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top